

**DON'T
LOOK
BACK**

MAVIRET FOR THE TREATMENT OF CHRONIC HEPATITIS C

TALK TO YOUR DOCTOR ABOUT MAVIRET

MAVIRET® is a prescription medicine used to treat adults with chronic (long-lasting) hepatitis C (hep C) virus.

MAVIRET belongs to a group of medicines called direct-acting antiviral agents (DAAs). MAVIRET is a combination of two medicines, glecaprevir and pibrentasvir, that work together to stop the hep C virus from multiplying and infecting new cells. This allows the infection to be eliminated from the body.

Based on clinical trials, 98% of people who take MAVIRET as directed and who are new to treatment and with no liver scarring (cirrhosis) can expect to be cured* of their hep C, meaning that the hep C virus has been cleared from the body.

*Cure means the hep C virus is not found in the blood 3 months after treatment ends.

QUESTIONS ABOUT MAVIRET TO DISCUSS WITH YOUR DOCTOR

Will MAVIRET cure my hep C?

How long would I have to take MAVIRET?

Are there any side effects with MAVIRET?

If I have other illnesses, is MAVIRET right for me?

If MAVIRET is right for me, which pharmacy will I pick it up from? You can only get MAVIRET from certain pharmacies. (Find pharmacy locations at www.maviret.co.nz)

Be sure to tell your doctor about all the medicines you take, including prescription and over-the counter medicines, vitamins and herbal supplements. It is also important to tell your doctor if you are hepatitis B positive.

Notes:

References: 1. MAVIRET Approved Consumer Medicine Information. 2. MAVIRET Approved Data Sheet. 3. Puoti M et al. Journal of Hepatology (2018), doi: <https://doi.org/10.1016/j.jhep.2018.03.007>

MAVIRET is a fully funded prescription medicine with an alternative arrangement on how it is available to you. Your prescriber will explain this to you.

IMPORTANT INFORMATION ABOUT MAVIRET®

MAVIRET is a prescription medicine containing a combination tablet of 100 mg of glecaprevir and 40 mg of pibrentasvir. It is used to treat chronic (long-lasting) hepatitis C virus (HCV) in adults. This medicine belongs to a group of medicines called direct-acting antiviral agents. Ask your doctor if you have any questions about why MAVIRET has been prescribed for you. **MAVIRET has risks and benefits.** You must not take MAVIRET if you are allergic to any of the medicines contained in MAVIRET, or to any of the inactive ingredients. Do not take it if you have severe liver disease; if you are taking atazanavir or rifampicin containing products. Before you use MAVIRET, tell your doctor if you have or have had liver problems other than hepatitis C infection, HIV infection, hepatitis B infection, or a liver or kidney transplant. Tell your doctor or pharmacist if you are pregnant, trying to become pregnant or if you are breastfeeding or are planning to breastfeed. Do not give MAVIRET to a child under the age of 18 years. Some medicines and MAVIRET may interfere with each other, so tell your doctor if you are taking medicines containing any of the following: atorvastatin, simvastatin, pravastatin, rosuvastatin, lovastatin, carbamazepine, ciclosporin, darunavir, lopinavir, ritonavir, efavirenz, dabigatran, digoxin, ethinyloestradiol, fluindione, warfarin or other vitamin K antagonists, St John's wort. Tell your doctor, nurse or pharmacist if you notice anything that is making you feel unwell. Some of the more common side effects of MAVIRET include feeling very tired, headache and nausea.

If you have any questions about using MAVIRET, including its risks and benefits, how much to use, how and when to use it, ask your healthcare professional and refer to the Consumer Medicine Information (CMI) available from your pharmacist, from the Medsafe website www.medsafe.govt.nz or free phone 0800 900 030. Ask your doctor if MAVIRET is right for you. Normal doctor's charges apply. Always use strictly as directed. If symptoms continue, or you have side effects, see your healthcare professional.

AbbVie Limited, 6th floor, 156-158 Victoria Street, Wellington 6011, New Zealand. TAPS PP2195. NZ-MAVI-180021. MAV0002. Date of Preparation November 2018.